At a glance
ClinicalIndex Comparison RecordN/ACompleted· 260 enrolled
Drug / intervention
Rituximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
OLYMPE - Prospective Cohort Study on the Management of Patients With Relapsed Follicular Lymphoma
In Brief
An observational study evaluating Rituximab for Follicular Lymphoma. Completed, enrolled 260 participants across 1 site.
Detailed Summary
This French national, multicenter, prospective, longitudinal, observational study will describe the treatment modalities of a cohort of patients with relapsed or refractory follicular non-Hodgkin's lymphoma, with evaluation of the cohort overall and according to the presence or not of MabThera® (rituximab) maintenance therapy. Actively participating physicians will enroll patients and collect therapeutic management data in a real-life setting up to 5 years.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
Primary CompletionApr 2013
First PostedDec 2014
TodayJul 2026
First PostedDec 15, 2014
Enrollment StartFeb 1, 2007
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 11.5 years ago
Interventions
Rituximabdrug